NCT06896422View on ClinicalTrials.gov

Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC

PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Non-Small Cell Lung CancerChemotherapyPD1 AntibodyGlutathione
Interventions
DRUG

Glutathione

Glutathione is administered as an adjunct intervention to the PD-1 inhibitor plus chemotherapy regimen.

DRUG

PD1 Inhibitor

e.g. pembrolizumab, camrelizumab, sintilimab, tislelizumab, toripalimab

DRUG

Chemotherapy

Platinum-based doublet chemotherapy

Trial Locations (1)

450052

RECRUITING

the First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Zhengzhou University

OTHER